Related stories
Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?
A Tax Strategy So Aggressive It Built the World’s Largest Hedge Fund and Made Losing Money the Hottest Product on Wall Street
Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside?
The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.
Prediction: Oklo Won't Book Its First Commercial Power Revenue Before 2028
Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?